Involvement of DPP‐IV catalytic residues in enzyme–saxagliptin complex formation

The inhibition of DPP‐IV by saxagliptin has been proposed to occur through formation of a covalent but reversible complex. To evaluate further the mechanism of inhibition, we determined the X‐ray crystal structure of the DPP‐IV:saxagliptin complex. This structure reveals covalent attachment between S630 and the inhibitor nitrile carbon (C–O distance <1.3 Å). To investigate whether this serine addition is assisted by the catalytic His‐Asp dyad, we generated two mutants of DPP‐IV, S630A and H740Q, and assayed them for ability to bind inhibitor. DPP‐IVH740Q bound saxagliptin with an ∼1000‐fold reduction in affinity relative to DPP‐IVWT, while DPP‐IVS630A showed no evidence for binding inhibitor. An analog of saxagliptin lacking the nitrile group showed unchanged binding properties to the both mutant proteins, highlighting the essential role S630 and H740 play in covalent bond formation between S630 and saxagliptin. Further supporting mechanism‐based inhibition by saxagliptin, NMR spectra of enzyme–saxagliptin complexes revealed the presence of three downfield resonances with low fractionation factors characteristic of short and strong hydrogen bonds (SSHB). Comparison of the NMR spectra of various wild‐type and mutant DPP‐IV:ligand complexes enabled assignment of a resonance at ∼14 ppm to H740. Two additional DPP‐IV mutants, Y547F and Y547Q, generated to probe potential stabilization of the enzyme–inhibitor complex by this residue, did not show any differences in inhibitor binding either by ITC or NMR. Together with the previously published enzymatic data, the structural and binding data presented here strongly support a histidine‐assisted covalent bond formation between S630 hydroxyl oxygen and the nitrile group of saxagliptin.

[1]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.

[2]  R. Shulman,et al.  High resolution nuclear magnetic resonance study of the histidine--aspartate hydrogen bond in chymotrypsin and chymotrypsinogen. , 1972, Journal of molecular biology.

[3]  S. French,et al.  On the treatment of negative intensity observations , 1978 .

[4]  P. J. Hore,et al.  Solvent suppression in Fourier transform nuclear magnetic resonance , 1983 .

[5]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[6]  J. Navaza,et al.  AMoRe: an automated package for molecular replacement , 1994 .

[7]  P. Frey,et al.  A new concept for the mechanism of action of chymotrypsin: the role of the low-barrier hydrogen bond. , 1997, Biochemistry.

[8]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[9]  L. Polgár,et al.  Low Barrier Hydrogen Bond Is Absent in the Catalytic Triads in the Ground State but Is Present in a Transition-state Complex in the Prolyl Oligopeptidase Family of Serine Proteases* , 1997, The Journal of Biological Chemistry.

[10]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[11]  P. Frey,et al.  Fractionation factors and activation energies for exchange of the low barrier hydrogen bonding proton in peptidyl trifluoromethyl ketone complexes of chymotrypsin. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  T. Hughes,et al.  NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. , 1999, Biochemistry.

[13]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[14]  Victor S. Lobanov,et al.  High-Density Miniaturized Thermal Shift Assays as a General Strategy for Drug Discovery , 2001 .

[15]  C. Durinx,et al.  Kinetic Investigation of Chemokine Truncation by CD26/Dipeptidyl Peptidase IV Reveals a Striking Selectivity within the Chemokine Family* , 2001, The Journal of Biological Chemistry.

[16]  Bo Ahrén,et al.  Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. , 2002, Diabetes care.

[17]  Robert N. Goldberg,et al.  Thermodynamic Quantities for the Ionization Reactions of Buffers , 2002 .

[18]  T. Hughes,et al.  1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. , 2002, Journal of medicinal chemistry.

[19]  A. D'arcy,et al.  High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[([2-[(5-iodopyridin-2-yl)amino]-ethyl]amino)-acetyl]-2-cyano-(S)-pyrrolidine. , 2003, Acta crystallographica. Section D, Biological crystallography.

[20]  Sven Branner,et al.  Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog , 2003, Nature Structural Biology.

[21]  Eberhard Standl,et al.  Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. , 2004, Diabetes care.

[22]  Biching Sang,et al.  Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation , 2004, Protein science : a publication of the Protein Society.

[23]  Xin Chen,et al.  One Site Mutation Disrupts Dimer Formation in Human DPP-IV Proteins* , 2004, Journal of Biological Chemistry.

[24]  Sven Branner,et al.  Tyrosine 547 Constitutes an Essential Part of the Catalytic Mechanism of Dipeptidyl Peptidase IV* , 2004, Journal of Biological Chemistry.

[25]  G. Scapin,et al.  (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[26]  R. Parker,et al.  Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[27]  Giovanni Pacini,et al.  Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. , 2005, Diabetes care.

[28]  Michael L Doyle,et al.  Decrypting the Biochemical Function of an Essential Gene from Streptococcus pneumoniae Using ThermoFluor® Technology* , 2005, Journal of Biological Chemistry.

[29]  W. Metzler,et al.  Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118). , 2006, Archives of biochemistry and biophysics.